Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Eloxatin (Oxaliplatin) – US: CAFC reverses District Court finding that generic Eloxatins do not infringe Sanofi’s patent; More claim construction confusion: Sanofi-Aventis v Sandoz (Patent Docs) (Patents4Life) (GenericsWeb)

Mircera (Erythropoietin) – US: CAFC affirms most of the determinations of District Court and jury, permanent injunction barring Roche from marketing Mircera in US remains: Amgen v Hoffman-La Roche (Patent Docs)

Controlled-release formulations a popular strategy for generic drug companies (GenericsWeb)

Africa: Counterfeit medicine news (Afro-IP)

Australia: Full Federal Court: Faculty hired to do research, not invent: University of Western Australia v Gray (Patent Baristas)

EU: Community plant variety system: how much does it cost? (IP finance)

US: A human by any name is still a human (even if it’s an animal): Martek Biosciences v Nutrinova (Patent Baristas)

US: BIO news conference: Biotech will lead healthcare and energy reform (Patent Baristas) (Patent Docs)

US: Patent extension for human drugs in the US: a fresh critique (The SPC Blog)

US: Change is afoot in Senate Reverse Payment Bill (FDA Law Blog)

US: ChemBridge makes chemical libraries available via public access database (Patent Docs)

Allegra (Fexofenadine) – US: AMRI files new patent infringement lawsuits against Dr Reddy’s and Sandoz over generic versions of Sanofi-Aventis’ Allegra (SmartBrief)

Eloxatin (Oxaliplatin) – US: CAFC reverses District Court finding that generic Eloxatins do not infringe Sanofi’s patent; More claim construction confusion: Sanofi-Aventis v Sandoz (Patent Docs) (Patents4Life) (GenericsWeb)

Femcon and Loestrin 24 FE (Norethindrone / Ethinyl estradiol) – US: Warner Chilcott files new lawsuit against Lupin for infringement of Loestrin and Femcon (SmartBrief) (Patent Docs) (GenericsWeb)

Lotrel (Amlodipine / Benazepril) – US: Lupin, Novartis settle Lotrel patent dispute (GenericsWeb)

Mircera (Erythropoietin) – US: CAFC affirms most of the determinations of District Court and jury, permanent injunction barring Roche from marketing Mircera in US remains: Amgen v Hoffman-La Roche (Patent Docs)

Naropin (Ropivacaine) – US: Navinta appeals District Court’s decision finding infringement of Naropin patents (Patent Docs)

Precedex (Dexmedetomidine) – US: Hospira files patent infringement suits against Sandoz in response to Para IV challenge (Patent Docs)

Renegal (Sevelamer) – US: Endo files motion to intervene in Renegal infringement dispute between Genzyme and Impax (Patent Docs)

Starlix (Nateglinide) – US: FDA resolves eligible/ineligible first applicant 180-day exclusivity forfeiture issue in the context of generic Starlix tablets (FDA Law Blog)

Ultram (Tramadol) – US: Purdue files patent infringement suits against Paddock in response to Para IV challenge (Patent Docs)

Ultram (Tramadol) – US: Purdue files appeal with CAFC seeking to overturn decision invalidating their Ultram patents (Patent Docs)